Cilcare Expands Hearing Loss Drug Pipeline with Two New Sanofi Agreements

sanofi stake cilcare
HHTM
November 16, 2026

MONTPELLIER, FRANCE — Hearing therapeutics company Cilcare has announced two exclusive licensing agreements with pharmaceutical company Sanofi covering investigational drug candidates targeting different biological mechanisms associated with hearing loss.

The agreements cover CIL005, a program targeting inflammation in the cochlea, and CIL006, which targets oxidative stress, with an initial focus on a rare hearing disorder. Both programs will undergo further preclinical development before potentially advancing toward human clinical trials.

The additions expand Cilcare’s therapeutic pipeline beyond cochlear synaptopathy, a condition involving damage to the connections between sensory hair cells and auditory nerve fibers that is the focus of its lead drug candidate, CIL001.

Financial terms of the new licensing agreements were not disclosed.

Targeting Inflammation and Oxidative Stress in the Inner Ear

Hearing loss can result from several different forms of damage within the auditory system. While some investigational treatments focus on sensory hair cells or the neural connections responsible for transmitting sound information, other approaches seek to address biological processes that contribute to cochlear injury.

Cilcare’s two new programs are designed to investigate these additional mechanisms.

CIL005: Cochlear Inflammation

CIL005 targets inflammatory processes within the cochlea. Inflammation can contribute to inner ear damage following excessive noise exposure, treatment with certain ototoxic medications, infections, or autoimmune conditions.

Although inflammation is part of the body’s normal response to injury, excessive or prolonged inflammatory activity can contribute to cellular damage and potentially worsen auditory function.

By targeting cochlear inflammation, Cilcare aims to investigate whether modifying these processes could help prevent or limit hearing damage in selected patient populations. However, the company has not yet reported clinical evidence demonstrating that CIL005 can prevent or reverse hearing loss.

CIL006: Oxidative Stress

CIL006 focuses on oxidative stress, a process that occurs when the production of reactive oxygen species exceeds the ability of cells to neutralize them. Excessive oxidative stress can damage cellular structures and has been implicated in several forms of cochlear injury.

Oxidative stress has been studied in connection with noise-induced hearing loss, age-related auditory changes, and certain forms of drug-induced hearing damage.

According to Cilcare, the initial development strategy for CIL006 will focus on a rare hearing disorder, although the company has not identified the specific condition in its announcement.

Both programs remain at an early stage. Cilcare plans to advance them through preclinical proof-of-concept studies using its experimental disease models and expertise in auditory research. The company has not announced timelines for clinical trials.

Building on an Existing Relationship with Sanofi

The latest agreements build on an established relationship between Cilcare and Sanofi, which is also a minority shareholder in the biotechnology company.

The companies have previously collaborated on Cilcare’s hearing therapeutics pipeline, including programs focused on cochlear synaptopathy. The addition of CIL005 and CIL006 reflects a broader strategy of investigating treatments for different biological causes of auditory dysfunction rather than relying on a single therapeutic approach.

“Our strategy is to build a differentiated pipeline that reflects the biological diversity of hearing disorders and addresses significant unmet medical needs. CIL005 and CIL006 broaden the scope of our portfolio, allowing us to target distinct disease mechanisms and expand into patient populations with limited therapeutic options,” said Patricia Machado, Early Drug Development and Pipeline Director at Cilcare.

The company has also been expanding its hearing research capabilities through partnerships involving hearing assessment and clinical data collection.

In a recently announced collaboration with Sonup, Cilcare outlined plans to incorporate remote hearing assessment technologies into selected clinical research protocols. The partnership is intended to support repeated auditory measurements and help researchers evaluate changes in hearing function over time.

These types of assessment tools could become increasingly relevant as researchers investigate treatments targeting specific mechanisms of hearing loss and seek more sensitive ways to measure therapeutic effects.

What the Agreements Mean for Hearing Healthcare

For hearing healthcare professionals, the announcement reflects continued investment in pharmaceutical approaches to auditory disorders, an area that remains largely investigational compared with established interventions such as hearing aids and cochlear implants.

The biological processes targeted by CIL005 and CIL006 are not new areas of hearing research. Inflammation and oxidative stress have been investigated for years as contributors to cochlear damage. The challenge has been translating laboratory findings into treatments that demonstrate meaningful, reproducible benefits in patients.

Developing effective therapies will require researchers to identify which patients may benefit, determine appropriate treatment timing, establish safety, and demonstrate improvements in clinically relevant auditory outcomes.

Because the two programs are still in preclinical development, it remains uncertain whether either will progress into human trials or ultimately become an approved treatment.

Celia Belline, Chief Executive Officer of Cilcare, emphasized the importance of expanding the company’s research portfolio and its relationship with Sanofi.

“These programs strengthen and diversify our pipeline, and further validate our ability to identify and advance promising opportunities in hearing health. They also reflect our continued partnership with Sanofi, our minority shareholder”, Belline said.

For now, the significance of the announcement lies primarily in the expansion of Cilcare’s research portfolio. By pursuing drug candidates aimed at cochlear inflammation, oxidative stress, and synaptic damage, the company is exploring multiple biological pathways that could eventually contribute to more targeted treatments for hearing disorders.

About Cilcare

Cilcare is a biopharmaceutical company pioneering auditory science, developing drugs and diagnostic tools to prevent and treat hearing disorders. Building on its expertise in auditory neuroscience, Cilcare develops its own pipeline while supporting industrial and academic partners worldwide in their preclinical and clinical programs. Headquartered in Montpellier, France, Cilcare operates in Europe, North America and Asia. For more information, visit www.cilcare.com.


Source: Cilcare, “Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi,” November 16, 2026.

Email Marketing by Benchmark